Your trusted source for investing success
By Shelly Kumar
Lexaria Bioscience Corporation (CSE:LXX,OTCQB:LXRP) announces it will be attending and delivering a presentation at the upcoming Canadian Securities Exchange sponsored “Cannabis in the Capital Markets” event on September 27 located in Kelowna, British Columbia. Also presenting at the event will be Dr. Philip Ainsle, Co-Director of the Centre for Heart, Lung
The Investing News rounds some of the biggest news in the cannabis market for the past trading week
What if the “one-size-fits-all” approach to medicine isn’t the right way treat medical conditions? Could a personalized medicine approach provide better treatment?
Spectral Medical announced it has been engaged in an ongoing interactive review process with the FDA, after its acceptance submission for Toraymyxin.
BioCryst Pharmaceuticals announced the FDA approved a supplemental new drug application for RAPIVAB.
Medical devices are differentiated three different ways. Here, the Investing News Network looks at class 3 medical devices.
Elite Pharmaceuticals filed an abbreviated new drug application with the FDA for a generic version of OxyContin.
The biotech sector has steadily enjoyed an increase this year, in part thanks to significant advancements and in spite of the uncertainty from the White House as the proposal of a new healthcare bill holds the grip of most life science markets.
The Investing News Network (INN) takes a closer look at the top biotech companies listed on the NASDAQ so far this year, with a market cap between 50 and 500 million.
ALR Technologies announced the US Food and Drug Administration granted clearance for their innovative insulin dose adjustment (IDA) feature of the ALRT diabetes management system.
Nabriva Therapeutics plc saw its stock get a major boost on Monday morning after the company announced top-line results from their trial of a pneumonia drug.
Oncolytics Biotech shared the results from a positive End-of-Phase 2 meeting with the FDA for REOLYSIN in combination with paclitaxel.
Aeolus Pharmaceuticals announced it met its primary endpoint for a phase 1 ascending dose escalation study.
By Shelly Kumar
DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI), a biopharmaceutical company focused on the development of new cancer therapies, today announced that the U.S. Food and Drug Administration (“FDA”) has allowed an additional Investigational New Drug Application (“IND”) to study its lead drug candidate VAL-083 as a potential treatment for ovarian cancer.
“The opening of this
CASI Pharmaceuticals, Savara, Adverum Biotechnologies, ChromaDex Therapeutics and MannKind top the NASDAQ biotech stock list.
CASI Pharmaceuticals, Savara, Adverum Biotechnologies, ChromaDex Therapeutics and MannKind top the NASDAQ biotech stock list.
The Investing News rounds some of the biggest news in the cannabis market for the past trading week
The global stem cell therapy market is expected to grow at a CAGR of 36.52 percent between 2017 and 2021. Here are 10 top stem cell companies on the NASDAQ.
The medical device industry is robust and diverse. Here are four small medical device companies that investors should watch.
Major players in the pharmaceutical industry include Johnson & Johnson, Novartis, Roche, Pfizer and Merck.
